. [82] to assess the efficacy, security and tolerability of Cannabidiol being an adjunct therapy in addition to anti-epileptic medications within the people struggling from tuberous sclerosis complex whose most commonly encountered neurological symptom is epilepsy. With this scientific trial analyze, just after cure with Cannabidiol, responder leve